

OCT 1 1 2005

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450 www.uspto.gov

Office of Regulatory Policy HFD - 13 5600 Fishers Lane Rockville, MD 20857

Attention: Claudia Grillo

The attached application for patent term extension of U.S. Patent No. 6,034,239 was filed on September 7, 2005, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, ROZEREMTM (ramelteon), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to Kathleen Kahler Fonda, Legal Advisor, at (571) 272-7754 (telephone).

Karin Ferriter

Senior Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc:

Mark Chao, Ph.D., J.D.

Takeda Pharmaceuticals North America, Inc.

475 Half Day Road Lincolnshire, IL 60069